TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02538900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants in one of the exercise intervention groups will attend once weekly sessions at the medical center for the first four weeks of the study (Weeks 1-4, Phase I). During weeks 5-52 (Phase II), they will receive weekly telephone calls from a study coach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants in one of the exercise intervention groups will attend once weekly sessions at the medical center for the first four weeks of the study (Weeks 1-4, Phase I). During weeks 5-52 (Phase II), they will receive weekly telephone calls from a study coach.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention control
Description: Our attention control group controls for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention. Participants randomized to the control group will attend weekly one-hour educational sessions at Northwestern University for the first four weeks of the intervention (Phase I). These sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, and cancer screening. During Phase II (weeks 5-52), the attention control group will receive weekly telephone calls, lasting 5-15 minutes, with information on a health-related topic.
Study: NCT02007590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerosure 25 Hz
Description: Active Aerosure device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Aerosure Sham
Description: Device designed to appear identical to active device but with HFAO mechanism disabled
Study: NCT03785405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Description: Target dose 3.1 mg/kg bid~Formulations:~Tablets (50, 100, 200 mg) Granules \[12.5 mg (4 granules), 31.25 mg (10 granules), in capsules\] Liquid (1 mg/ml, 4 mg/ml, prepared from tablets)
Study: NCT01290341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAFT-600 (naftin 2 % gel)
Description: Topical; applied once daily for two weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical; applied once daily for two weeks.
Study: NCT01483066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShapeMatch Technology
Description: ShapeMatch Technology places a plastic cutting guide on the end of the femur and tibia, so that cuts that do not automatically default to the mechanical axis, but rather attempt to recreate the patient's anatomic alignment.
Study: NCT01085019

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black pepper
Description: 2.8g/day of black pepper in capsules for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2.8 g/day of placebo in capsules (corn starch) during 4 weeks.
Study: NCT02025049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-b99
Description: DP-b99 is a lipophilic analog of the divalent metal ion chelator O,O'-Bis(2-aminophenyl) ethyleneglycol-N,N,N',N'-tetraacetic acid (BAPTA)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: mannitol-based DP-b99 look-alike
Study: NCT00790530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Telephone Outreach with Speech Recognition
Description: Automated Telephone Outreach with Speech Recognition

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Usual Care
Description: Usual Care
Study: NCT02327156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: adding dexmedetomidine to the local anesthetic
Study: NCT02331641

Intervention type: PROCEDURE
Intervention: Hepatectomy
Description: Removal of a part of the liver

Intervention type: PROCEDURE
Intervention: Hepatectomy
Description: Removal of a part of the liver
Study: NCT04182906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Coordination
Description: Screening and referral for basic needs and adult mental health

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Coordination
Description: Screening and referral for basic needs and adult mental health

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resiliency Clinic
Description: Mindfulness-based caregiver-child group medical care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resiliency Clinic
Description: Mindfulness-based caregiver-child group medical care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Primary Pediatric Care
Study: NCT03591913

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Oral tablets
Study: NCT02500472

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kava
Description: 3 doses equaling 250 mg kavalactones per day. Participants will take 1 capsule three times daily at 8:00 (± 2 hours), 14:00 (± 2 hours) and 20:00 (± 2 hours) for 7 consecutive days.
Study: NCT04066699

Intervention type: PROCEDURE
Intervention: Percutaneous localization of suspicious lung lesion(s) using electromagnetic navigation and tools.
Description: Transthoracic localization of suspicious lung lesion(s) in preparation for subsequent resection.
Study: NCT02798562

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Native and dynamic contrast-enhanced CT
Study: NCT01170949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Description: 50 or 100 or 150mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01787851

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Triheptanoin oil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triheptanoin oil
Study: NCT03499340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: text-only PWL
Description: control condition (no image)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: text-only PWL
Description: control condition (no image)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low arousal graphic PWL
Description: pictorial warning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low arousal graphic PWL
Description: pictorial warning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high arousal graphic PWL
Description: pictorial warning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high arousal graphic PWL
Description: pictorial warning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: absolute risk
Description: Percentage risk information for smoking-related diseases for smokers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: absolute risk
Description: Percentage risk information for smoking-related diseases for smokers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: absolute risk
Description: Percentage risk information for smoking-related diseases for smokers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relative risk
Description: Percentage risk information for smoking-related diseases for smokers and non-smokers
Study: NCT00297830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Alendronate 70 mg will be taken once a week in the morning at least 30-60 minutes before first meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Zoledronic Acid
Description: Infusion of placebo zoledronic acid during the first 5 weeks after transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Alendronate
Description: Placebo alendronate 70 mg once weekly
Study: NCT03499340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relative risk
Description: Percentage risk information for smoking-related diseases for smokers and non-smokers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relative risk
Description: Percentage risk information for smoking-related diseases for smokers and non-smokers
Study: NCT04049812

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEMF

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hot pack

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Hot pack

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham PEMF
Study: NCT01966159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNERGY Investigational Device
Description: percutaneous coronary intervention
Study: NCT02709109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-371 + HS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-371 + HS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01966159

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PE Plus Investigational Device
Description: percutaneous coronary intervention
Study: NCT02709109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orkambi

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orkambi

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orkambi

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orkambi

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-371
Study: NCT03769337

Intervention type: DIAGNOSTIC_TEST
Intervention: serum biomarkers
Description: Measurement of Serum concentrations of IL-6, TREM-1, CCL2, MMP-9, OPN, IL-1RA, GP-130, C5a, sRAGE, urokinase and presepsin before revision surgery and after 2 and 7 days after surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: serum biomarkers
Description: Measurement of Serum concentrations of IL-6, TREM-1, CCL2, MMP-9, OPN, IL-1RA, GP-130, C5a, sRAGE, urokinase and presepsin before revision surgery and after 2 and 7 days after surgery
Study: NCT01062828

Intervention type: DIAGNOSTIC_TEST
Intervention: Citrulline samples
Description: Citrulline samples will be collected at the time of other lab work twice a week from enrollment until 40 weeks postconceptional age and once a week until 44 weeks postconceptional age (1 month corrected age) OR discharge from NICU(whichever is soonest). In subgroup developing NEC, citrulline samples will be collected twice a week from enrollment until discharge from NICU or death.
Study: NCT00064077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study: NCT03725202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: It will be administered orally.
Study: NCT00064077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Tartrate
Description: Given IV
Study: NCT02959112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sterile water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin Rectal Suppository

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indomethacin Rectal Suppository
Study: NCT00689169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan)
Description: Zevalin 0.4 mCi/kg: D-14 BCNU 300 mg/m² : D-6 Etoposide 100 mg/m²/12h : D-6 D-5 D-4 D-3 Aracytine 200 mg/m²/12h : D-6 D-5 D-4 D-3 Melphalan 140 mg/m²: D-2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ASCT
Description: ASCT : D0
Study: NCT01483066

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ShapeMatch Technology
Description: ShapeMatch Technology places a plastic cutting guide on the end of the femur and tibia, so that cuts that do not automatically default to the mechanical axis, but rather attempt to recreate the patient's anatomic alignment.
Study: NCT01450163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin, Oxaliplatin
Description: Oxaliplatin will be infused according to the FLOX treatment strategy, as a regular six-month-long adjuvant treatment to colorectal cancer. Pregabalin will be administered P.O. three days before and three days after each of the nine Ox infusions. The dose will be titrated during the first Ox infusion to the highest level tolerated by the patient. The dose used in this first session will be used in the eight following sessions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo , Oxaliplatin
Description: Oxaliplatin will be infused according to the FLOX treatment strategy, as a regular six-month-long adjuvant treatment to colorectal cancer. Placebo will be administered P.O. three days before and three days after each of the nine Ox infusions. The dose will be titrated during the first Ox infusion to the highest level tolerated by the patient. The dose used in this first session will be used in the eight following sessions.
Study: NCT00689169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 250 mg/m² :D-21 D-14
Study: NCT01923571

Intervention type: OTHER
Intervention: intraoperative BGC measure

Intervention type: OTHER
Intervention: intraoperative BGC measure
Study: NCT00054184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel poliglumex
Study: NCT04625985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Glycinate
Description: Participants randomized to metformin glycinate will take 620 mg bid (PO) for 14 days plus standard treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Participants randomized to placebo will take a tablet bid (PO) for 14 days in plus standard treatment
Study: NCT02426112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04907864

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Multi-modal intervention
Description: Daily oral medications: ibuprofen 400 mg three times a day, omega-3-fatty acid 1 g twice a day, Bojungikki-tang 3.75g twice a day, oral nutritional supplement (HAMONILAN SOLN) 200 ml twice a day Weekly physical exercise by physiatrist (60 minutes per visit) Biweekly psychiatric intervention Nutritional counselling total four times during the study period
Study: NCT03725202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: It will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid (CS)
Description: It will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid (CS)
Description: It will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroid (CS)
Description: It will be administered orally.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It will be administered orally.
Study: NCT04178564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation
Description: The intervention includes 50 sessions, over the course of one year, being that 3 of those sessions will be the pretest, intratest and posttest evaluations. The intervention sessions will last approximately 60 minutes and they will be developed according to the following structure:~Welcoming to the group (5 minutes) Reality orientation therapy (10 minutes) Main activity (35 minutes) Session evaluation (10 minutes) CS sessions will be conducted in groups. The intervention sessions will include several activities based on different non-pharmacological therapies, whose effectiveness in elderly with neurocognitive disorders has been scientifically proven. Non-pharmacological therapies used encompass therapies such as musictherapy, reminiscence therapy, validation therapy, Montessori method in geriatrics, ADL training, art therapy and the computer software Rehacom.
Study: NCT01619696

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic MRI and F MISO TEP
Description: Pelvic MRI and F MISO TEP: before inclusion, 2 weeks after beginning and 7 weeks after completion of chemoradiotherapy.
Study: NCT01562418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ergonomic intervention
Description: Ergonomic intervention, how to sit and work, an d muscle re education with a SurfaceElrctromyograph Biofeedback (SEMG biofeedback)
Study: NCT03872557

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tyrosine (TYR) Supplementation
Description: L-Tyrosine dietary supplement will be provided as 500 mg capsules and 4 (four) 500 mg capsules are to be given before OGTT. The capsules are formed from animal gelatin, and the contents are formulated with magnesium stearate as a flow agent, but without binders, coatings or colorings and also have no added flavorings, sugars, salt, artificial sweeteners, preservatives or salicylates. The capsules are to be administered with less than eight ounces of water to minimize dilution of gastric acidity.
Study: NCT00655811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin
Description: Topical application, 0.1%, Capzasin HP; Chattem Inc., Chattanooga, TN, U.S.A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo moisturizing cream
Description: Placebo moisturizing cream with no active ingredient (Cetaphil; Galderma Laboratories LP, Fort Worth, TX, U.S.A.)
Study: NCT01962857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 4-week supervised high intensity shuttle running intervention, 3 sessions per week (12 sessions in total)
Study: NCT01832857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-613
Description: CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is the maximum tolerated dosing \[MTD\]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
Study: NCT01053572

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adhesiolysis
Description: Group I will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and non-particulate Celestone
Study: NCT01562418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard ergonomic intervention
Description: Standard ergonomic intervention , how to sit and work with computers

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: control group
Description: general instructions no intervention
Study: NCT01053572

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adhesiolysis
Description: Group I will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and non-particulate Celestone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adhesiolysis
Description: Group I will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and non-particulate Celestone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adhesiolysis
Description: Group I will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and non-particulate Celestone
Study: NCT00602069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Helping to Overcome PTSD through Empowerment (HOPE)
Description: HOPE includes a maximum of 16 sessions of cognitive behavioral therapy. The sessions will emphasize stabilization and empowerment, both of which are identified as important goals by the theoretical and empirical literature on abused women and PTSD.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual includes standard shelter services for abused women.
Study: NCT02970539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol
Description: Oraxol (Paclitaxel and HM30181A) will be dosed orally. Paclitaxel will be supplied as capsules and HM30181A will be supplied as tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab will be administered by iv infusion and supplied as a solution at a concentration of 10 mg/mL
Study: NCT03249753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127 200mg Panel A
Description: Participants who are in panel A will receive a single dose of a SPH3127 tablets 200mg when limosis, then fast 4h after dosing, and 72 hours later participants take the second dose of SPH3127 200mg after a high-fat breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127 200mg Panel B
Description: Participants who are in panel B will receive a single dose of a SPH3127 tablets 200mg after a high-fat breakfast, then 72 hours later participants take the second dose of SPH3127 200mg when limosis.
Study: NCT00355134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Fingolimod capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Fingolimod capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules for oral administration.